ArticleDiscover oncology2026
Skene's gland adenocarcinoma: a case report and review of the literature.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSkene’s gland adenocarcinoma is a rare female urethral neoplasm, there is no consensus regarding their treatment. CASE PRESENTATION: A 71 year-old patient complained frequency of urination increased, and the aggravation was accompanied with dysuria for more than 1 month. She underwent cystoscopy for stone removal and electrosurgery for bladder neck tumor. We describe the cystoscopic imaging, histologic, immunohistochemical, and clinical findings of the patient with Skene’s gland adenocarcinoma. MANAGEMENT: The patient underwent robot-assisted cystectomy with Bricker ileal conduit formation and regional lymph node dissection under general anesthesia. Postoperative stage pT3aN1, with no radiotherapy or chemotherapy after surgery. FOLLOW-UP: After 48 months of follow-up, the patient is currently in good condition with a cystostomy.
conclusionWe encourage physicians to take advantage of extensive knowledge and expanding tools in prostate cancer to manage Skene’s gland adenocarcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.